Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Angiosarcoma, drawn from the whole corpus: 6 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Multifocal scalp disease escapes even wide surgery and radiotherapy.
Median survival with metastases remains under a year.
Nothing recorded yet.
Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Immunotherapy benefit is limited to the ultraviolet-driven subset and has not been confirmed in a randomised trial.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 9 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Adding TRC105 to pazopanib did not improve progression-free survival; stopped for futility.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.